Drug Profile
BCH 2051
Alternative Names: BCH-2051Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Shire
- Class Antineoplastics; Naphthoquinones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 06 Dec 2000 Profile reviewed but no significant changes made
- 13 Aug 1998 Profile reviewed